Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is ...

During its most recent quarterly earnings, Johnson & Johnson announced plans to separate its Orthopedics business to enhance strategic and operational focus. The transaction would establish a ...

Next Tuesday will mark a profoundly sad anniversary. It will have been one year since the shooting death of Officer Enrique Martínez as he responded to call in Chicago’s Chatham neighborhood on the ...

Shares of Johnson & Johnson were rising into record territory in early trading Tuesday, after the medicines and medical-technology giant beat quarterly earnings expectations and raised its outlook, ...

Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter. The pharma company also announced it will spin off ...

Johnson & Johnson JNJ reported third-quarter results slightly ahead of consensus, inching up full-year guidance for reported revenue growth by 30 basis points to 5.7% at the midpoint while maintaining ...

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter ...

Shares of gun manufacturers spiked immediately following the assassination of conservative activist Charlie Kirk on a college campus Wednesday, a market trend that typically happens after high-profile ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Johnson & Johnson ( (JNJ)) has provided ...

SIOUX FALLS, S.D. (KELO/AP) — A bill in Washington with bipartisan backing would prevent members of Congress from trading of individual stocks. Among the supporters is South Dakota’s only member of ...

On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin. The 42.7% year-over-year decline in sales of its ...